Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Stacey, Helen L.; Rosen, Jeffrey B.; Peterson, James T.; Williams-Diaz, Angela; Gakhar, Vanita; Sterling, Tina; Acosta, Camilo J.; Nolan, Katrina M.; Li, Jianing; Pedley, Alison; Benner, Patrice; Abeygunawardana, Chitrananda; Kosinski, Michael; Smith, William J.; Pujar, Hari; Musey, Luwy

doi:10.1080/21645515.2018.1532249

Cited by 92 publications

(53 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main limitation of these vaccines is that serotype replacement is a frequent phenomenon that occurs after the massive use of these vaccines based on capsular polysaccharides due to the wide antigenic variability of this bacterium with up to 99 serotypes described so far and emergence of virulent clones with vaccineescape capsule (Brueggemann et al, 2007;Domenech et al, 2018). To target the emergence of non-vaccine types producing pneumococcal infection, a 15-valent conjugate vaccine (PCV15) including serotypes covered by PCV13 plus serotypes 22F and 33F is in clinical phase III with the advantage of inducing a higher title of antibodies against serotype 3 (Greenberg et al, 2018;Stacey et al, 2019). In addition, a 20-valent conjugate vaccine (PPV20) that contains serotypes in PCV15 plus serotypes 8, 10A, 12F, 11A, and 15B is also in clinical trials studies (Thompson et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

“…In contrast to Neisseria meningitidis, bactericidal activity by the membrane attack complex of the complement system plays a minor role against S. pneumoniae and killing by professional phagocytes in the presence or not of specific antibodies, is the most efficacy mechanism to fight the pneumococcal infection (Standish and Weiser, 2009). For this reason opsonophagocytosis killing assays (OPKA) are the best parameter to measure the functional opsonic activity of antibodies to S. pneumoniae when a new vaccine is tested (Greenberg et al, 2018;Stacey et al, 2019;Thompson et al, 2019). Hence, investigating these aspects will contribute to increase the knowledge about the potential of non-vaccine serotypes to produce infection in the host.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain

et al. 2020

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain

et al. 2020

View full text Add to dashboard Cite

“…The impact of vaccination on the pneumococcal pangenome before and after the introduction of PCV in Navajo and White Mountain Apache was investigated by Azarian and colleagues [77]. Population genetic analyses were consistent with a bottleneck effect following the introduction of PCV, followed by expansion of the nonvaccine type strains that made up the majority of the post vaccine population.…”

Section: New Frontiers In Pneumococcal "Omics" Genomics and Transmissionmentioning

confidence: 99%

“…The progress on the development of PCVs with broader valency, PCV15 [74] and PCV24 [75] as well as a lower cost PCV10 from the Serum Institute of India [76], were discussed. Stacey and colleagues demonstrated that two different preparations of PCV15 both have safety profiles comparable with that of PCV13 [77]. Both PCV15 formulations (PCV13 serotypes plus 22F and 33F) induced serotype-specific antibody responses to all 15 serotypes in the vaccine, and these responses were non-inferior to PCV13 for common serotypes, measured both by serotype-specific opsonophagocytic activity (OPA) and IgG geometric mean titers (GMCs).…”

Section: New Vaccines and New Trialsmentioning

confidence: 99%

State-of-the-art in the pneumococcal field: Proceedings of the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11)

2020

View full text Add to dashboard Cite

The International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD) is the premier global scientific symposium dedicated to the exchange, advancement and dissemination of the latest research on the pneumococcus, one of the world's deadliest bacterial pathogens. Since the first ISPPD was held in 1998, substantial progress has been made to control pneumococcal disease, for instance, more than half of surviving infants (78.6 million) from 143 countries now have access to the life-saving pneumococcal conjugate vaccine (PCV). The 11th ISPPD (ISPPD-11) was held in Melbourne, Australia in April 2018 and the proceedings of the symposium are captured in this report. Twenty years on from the first ISPPD, there remain many challenges and unanswered questions such as the continued disparity in disease incidence in Indigenous populations, the slow roll-out of PCV in some regions such as Asia, the persisting burden of disease in adults, serotype replacement and diagnosis of pneumococcal pneumonia. ISPPD-11 also put the spotlight on cutting-edge science including metagenomic, transcriptomic, microscopy, medical imaging and mathematical modelling approaches. ISPPD-11 was highly diverse, bringing together 1184 delegates from 86 countries, representing various fields including academia, primary healthcare, pharmaceuticals, biotechnology, policymakers and public health.

show abstract

“…Serotype replacement has been observed after introduction of conjugated pneumococcal vaccines (see section "Conjugation of Polysaccharide Antigens") and next-generation conjugated vaccines containing additional serotypes are being developed. Immunogenicity and safety of a 15-valent conjugated vaccine has been shown to be comparable to PCV-13 in early stage clinical trials (168). However, universal vaccines against S. pneumoniae would hopefully be able to fully overcome the risk of serotype replacement and would therefore probably have a more profound long-term clinical impact.…”

Section: Future Perspectives To Improve Vaccination Of the Older Popumentioning

confidence: 99%

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Wagner

Weinberger

2020

Front. Immunol.

View full text Add to dashboard Cite

Infectious diseases are a major cause for morbidity and mortality in the older population. Demographic changes will lead to increasing numbers of older persons over the next decades. Prevention of infections becomes increasingly important to ensure healthy aging for the individual, and to alleviate the socioeconomic burden for societies. Undoubtedly, vaccines are the most efficient health care measure to prevent infections. Age-associated changes of the immune system are responsible for decreased immunogenicity and clinical efficacy of most currently used vaccines in older age. Efficacy of standard influenza vaccines is only 30-50% in the older population. Several approaches, such as higher antigen dose, use of MF59 as adjuvant and intradermal administration have been implemented in order to specifically target the aged immune system. The use of a 23-valent polysaccharide vaccine against Streptococcus pneumoniae has been amended by a 13-valent conjugated pneumococcal vaccine originally developed for young children several years ago to overcome at least some of the limitations of the T cell-independent polysaccharide antigens, but still is only approximately 50% protective against pneumonia. A liveattenuated vaccine against herpes zoster, which has been available for several years, demonstrated efficacy of 51% against herpes zoster and 67% against post-herpetic neuralgia. Protection was lower in the very old and decreased several years after vaccination. Recently, a recombinant vaccine containing the viral glycoprotein gE and the novel adjuvant AS01B has been licensed. Phase III studies demonstrated efficacy against herpes zoster of approx. 90% even in the oldest age groups after administration of two doses and many countries now recommend the preferential use of this vaccine. There are still many infectious diseases causing substantial morbidity in the older population, for which no vaccines are available so far. Extensive research is ongoing to develop vaccines against novel targets with several vaccine candidates already being clinically tested, which have the potential to substantially reduce health care costs and to save many lives. In addition to the development of novel and improved vaccines, which specifically target the aged immune system, it is also important to improve uptake of the existing vaccines in order to protect the vulnerable, older population.

show abstract

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Cited by 92 publications

References 48 publications

Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain

Clinical Relevance and Molecular Pathogenesis of the Emerging Serotypes 22F and 33F of Streptococcus pneumoniae in Spain

State-of-the-art in the pneumococcal field: Proceedings of the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11)

Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives

Contact Info

Product

Resources

About